Crescendo Biologics is a provider of human VH antibody fragment therapeutics created to optimize antibodies and a transgenic mouse which produces heavy chain only antibodies. The Company develops potent, multi-functional Humabody, therapeutics in oncology with a proprietary pipeline focus on CB307, a unique targeted T-cell engager. It uses its VH fragment discovery platform to advance in-house development programs in inflammation and oncology, using transgenic mice.